Accessibility of therapy with T-lymphocytes with chimeric antigen receptor anti-CD19 in adult patients with B-cell leukemia and lymphomas

Authors:

Abstract
Introduction . Currently, therapy for hematological malignancies using chimeric antigen receptor T-cells (CAR T) has been included in Russian clinical recommendations. Aim : to highlight the medical and organizational aspects of the use and prospects for the development of therapy for hematological malignancies using CAR T-cell products in Russia. Main findings. Currently, CAR-T-cell therapy has been included in Russian clinical recommendations, and regulatory documents have been developed governing the manufacture and use of CAR T-cell products for patients with refractory and relapsed forms of CD19-positive malignant diseases of the blood system. To use a CAR T-cell product, it is necessary to obtain high-quality starting material via leukapheresis for further production. In Russia, centers for apheresis of hematopoietic stem cells exist only in those medical organizations where hematopoietic stem cell transplantation (HSCT) is performed. There are 36 such centers of federal and regional level in Russia for auto-HSCT and 19 for allo-HSCT. The number of patients in Russia who may be recommended anti-CD19 CAR T-cell therapy is about 2,500 people per year. However, given that not all patients for whom this therapy is indicated can undergo it, the actual number of cases of anti-CD19 CAR T-cell product use at present may be 250–300 (maximum 400) cases per year. In Russia, the use of CAR T-cell products occurs both in the form of a high-tech medicinal product and in the form of a biomedical cell product (BMCP). As of May 2026, there are already 3 centers in Russia that have received permission to manufacture and use an anti-CD19 CAR T-cell product in the format of an individual BMCP.

This publication has 19 references indexed in Scilit: